01—Abstract
Summary
Summary of the 10-K filed February 13, 2015. Cited figures are marked; the original filing is the authoritative source.
Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics.
As of their February 13, 2015, 10-K filing, the company was in the clinical stage of development, with no products yet approved for commercial sale. Their primary strategy centers on using proprietary RNAi technology, particularly their GalNAc-conjugate delivery system, to create novel treatments for a range of diseases. The company has outlined an "Alnylam 2020" plan, aiming for three marketed products and ten clinical programs by the end of 2020.
Key development areas include Genetic Medicines for rare diseases (with their most advanced program, patisiran, targeting transthyretin-mediated amyloidosis), Cardio-Metabolic Diseases (targeting conditions like hypercholesterolemia), and Hepatic Infectious Diseases (such as Hepatitis B). Significant recent events include a substantial public offering in January 2015, raising approximately $496.4 milliona in net proceeds, and a strategic collaboration with Genzyme announced in January 2014, which includes significant upfront payments and milestone potential.
Financially, Alnylam reported substantial operating losses, consistent with its development-stage status, with an accumulated deficit of $956.6 millionb at the end of 2014. Despite ongoing losses, the company ended 2014 with a strong cash position of $881.9 million in cash, cash equivalents, and marketable securities, bolstered by the January 2015 public offering and the Genzyme collaboration, providing runway for continued investment in their robust pipeline.
02—Key points
Key Highlights
- Alnylam is focused on RNAi therapeutics, a novel approach to gene silencing for disease treatment.
- The company has a "Alnylam 2020" plan aiming for three marketed products and ten clinical programs by 2020.
- Key programs include patisiran (ATTR), revusiran (ATTR), ALN-AT3 (hemophilia), ALN-PCSsc (hypercholesterolemia), and ALN-CC5 (complement-mediated diseases).
- A major strategic collaboration with Genzyme was entered into in January 2014, providing significant upfront capital and potential future milestone payments.
- In January 2015, Alnylam successfully raised approximately $496.4 million in net proceeds through a public stock offering.
- The company has substantial R&D expenses, indicative of its stage of development, with a focus on advancing its pipeline across Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases.
- As of year-end 2014, Alnylam maintained a strong liquidity position with $881.9 million in cash, cash equivalents, and marketable securities.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2014filed February 13, 2015Financial Statements
FY2014 against FY2013
| Line item | FY2014FY2013 | Change |
|---|---|---|
| R&D Expenses | $190.25M$112.96M | +68.4% |
| Operating Expenses | $455.54M$140.11M | +225.1% |
| Operating Income | -$404.98M-$92.94M | −335.7% |
| Net Income | -$360.39M-$89.22M | −303.9% |
| EPS (Basic) | $-4.85$-1.45 | −234.5% |
| Shares Outstanding (Basic) | 74.28M61.55M | +20.7% |
05—Questions
Frequently Asked Questions
What is Alnylam's core technology and therapeutic focus?
Alnylam's core technology is RNA interference (RNAi), which leverages a natural biological pathway to selectively silence and regulate gene expression. Their therapeutic focus is on developing RNAi therapeutics for a broad range of human diseases, with key areas including Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases.
What are the key development programs Alnylam is advancing?
Alnylam has several key development programs. In Genetic Medicines, patisiran (ALN-TTR02) for TTR-mediated amyloidosis is their most advanced, in Phase 3 trials. Revusiran (ALN-TTRsc) for ATTR cardiomyopathy is also in Phase 3. Other programs include ALN-AT3 for hemophilia (Phase 1), ALN-PCSsc for hypercholesterolemia (Phase 1), and ALN-AS1 for hepatic porphyrias (expected Phase 1 initiation in mid-2015).
How is Alnylam funding its operations and development?
Alnylam's operations are primarily funded through strategic alliances and collaborations with other companies, such as the significant collaboration with Genzyme. They also fund operations through equity financings, as evidenced by a large public offering in January 2015. The company expects continued losses from R&D activities for the foreseeable future and relies on these funding sources to advance its pipeline.
What is the significance of the Genzyme collaboration?
The strategic collaboration with Genzyme, initiated in January 2014, is crucial for Alnylam. It provides substantial upfront capital ($700 million cash payment and equity) and establishes a framework for worldwide development and commercialization of Alnylam's Genetic Medicines programs. This partnership accelerates the advancement of rare disease therapeutics and provides significant financial and operational support.
06—Continue